BioMarin Pharmaceutical (BMRN) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

BioMarin Pharmaceutical

NasdaqGS•Healthcare•Biotechnology

$66.41+0.73(0.01%)After hours

Market Cap

$12.37B

P/E

169.5x

P/S

3.6x

P/B

2.0x

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; and KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.

How this company scores

AverageMetricSide Score: 51/100

Strongest: Cash & Earnings Quality (23/25); weakest: Profitability (4/25).

Profitability4/25

Growth14/25

Balance Sheet & Red Flags10/25

Cash & Earnings Quality23/25

Strengths

Cash-backed earningsConsistent free cash flowConsistent growth

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 169.5x5y range 16.1x – 883.9x

Currently above its 19-quarter median.

P/S · 3.6x5y range 3.3x – 9.2x

Currently below its 20-quarter median.

P/B · 2.0x5y range 1.7x – 4.2x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

Operating margins dropped 83.1% over recent quarters — a sharp decline suggesting serious cost or pricing challenges.

Earnings Quality

Watch

FCF/Net Income has dropped below 0.7x in 3 quarters — monitor for earnings quality deterioration.

Price & Volume

Market Cap $12.37B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $3.41B
Q. Revenue: $989.71M
TTM EBITDA: $222.16M
TTM Op. Income: $149.26M
Q. Op. Income: $110.92M
TTM Net Income: $72.97M
Q. Net Income: $44.76M
EPS: $0.23
Shares Out.: $193.42M

$3.41B in TTM revenue grew 11.2% YoY, reaching $989.71M last quarter. TTM EBITDA of $222.16M and TTM operating income of $149.26M show growth is flowing through to the bottom line. TTM net income of $72.97M means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 79.5%
EBITDA Margin: 12.2%
Op. Margin: 11.2%
Net Margin: 4.5%

Op. margin of 11.2% is down 22.3% YoY — costs are rising relative to revenue. Net margin at 4.5% and gross margin of 79.5% show how much of each revenue dollar survives to profit. Over the past year, operating margin is down 67% — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 169.5x
P/S Ratio: 3.6x
P/B Ratio: 2.0x

At 169.5x P/E, the stock trades above typical market levels — the market expects above-average growth. P/S of 3.6x and P/B of 2.0x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Across the last 8 quarters, P/E has risen for 4 consecutive quarters — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $11.72B
Cash: $874.00M
Long-Term Debt: $3.53B
Book Value: $6.32B
D/E Ratio: 0.6
Debt/EBITDA: 29.3

With $11.72B in assets and $3.53B in long-term debt, D/E is 0.6and book value is $6.32B — a conservative capital structure with a cushion to weather downturns. Across the last 8 quarters, debt/equity has risen for 2 consecutive quarters — a weakening trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $168.11M
TTM Free Cash Flow: $738.18M
FCF Margin: 21.7%
FCF / Net Income: 10.1

TTM FCF of $738.18M on $168.11M in operating cash flow. The FCF / Net Income ratio of 10.1x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is up 6% — a weakening trend.